Similar Search Results

Strategic corporate social responsibility and orphan drug development : insights from the US and the EU biopharmaceutical industry

Bruyaka, Olga; Zeitzmann, Hanko K.; Chalamon, Isabelle; … - In: Journal of business ethics : JOBE 117 (2013) 1, pp. 45-65

Persistent link: https://www.econbiz.de/10010231737

Do fixed patent terms distort innovation? : evidence from cancer clinical trials

Budish, Eric B.; Roin, Benjamin N.; Williams, Heidi - 2013

Persistent link: https://www.econbiz.de/10010193836

A Ricardian-demand explanation for changing pharmaceutical R&D productivity

Pauly, Mark V.; Myers, Kyle - 2016

Persistent link: https://www.econbiz.de/10011563034

Starving (or fattening) the golden goose? : generic entry and the incentives for early-stage pharmaceutical innovation

Branstetter, Lee; Chatterjee, Chirantan; Higgins, Matthew J. - 2014

Persistent link: https://www.econbiz.de/10010421600

The effect of pharmaceutical innovation on longevity : patient-level evidence from the 1996-2002 medical expenditure panel survey and linked mortality public-use files

Lichtenberg, Frank R. - 2012

Persistent link: https://www.econbiz.de/10009679615

The captain of the men of death and his shadow : long-run impacts of early life pneumonia exposure

Bhalotra, Sonia R.; Venkataramani, Atheendar - 2011

We exploit the introduction of sulfa drugs in 1937 to identify the causal impact of exposure to pneumonia in infancy on later life well-being and productivity in the United States. Using census data from 1980-2000, we find that cohorts born after the introduction of sulfa experienced increases...

Persistent link: https://www.econbiz.de/10009516935

Pharmaceutical high profits : the vale of R&D, or oligopolistic rents?

Spitz, Janet; Wickham, Mark - In: The American journal of economics and sociology 71 (2012) 1, pp. 1-36

Persistent link: https://www.econbiz.de/10009518216

The effects of product liability exemption in the presence of the FDA

Philipson, Tomas J.; Sun, Eric; Goldman, Dana P. - In: Regulation versus litigation : perspectives from …, (pp. 137-163). 2011

Persistent link: https://www.econbiz.de/10009236132

When are assets compementary? : star scientists, strategic alliances, and innovation in the pharmaceutical industry

Hess, Andrew M.; Rothärmel, Frank T. - In: Strategic management journal 32 (2011) 8, pp. 895-909

Persistent link: https://www.econbiz.de/10009237567

Interactive financial decision support for clinical research trials

Holler, Benjamin; Forgione, Dana A.; Baisden, Clinton E.; … - In: Journal of health care finance 37 (2010/11) 3, pp. 25-37

Persistent link: https://www.econbiz.de/10008938508